454 related articles for article (PubMed ID: 34558414)
1. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
2. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
3. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
7. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
8. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
9. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
11. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
[TBL] [Abstract][Full Text] [Related]
12. ALK and ROS1 rearrangement tested by ARMS-PCR in non-small-cell lung cancer patients via cytology specimens: The experience of Shanghai Pulmonary Hospital.
Cao Z; Wu W; Zhang W; Li Z; Gao C; Huang Y; Zhang L
Diagn Cytopathol; 2020 Jun; 48(6):524-530. PubMed ID: 32150350
[TBL] [Abstract][Full Text] [Related]
13. The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Evans M; O'Sullivan B; Hughes F; Mullis T; Smith M; Trim N; Taniere P
Pathol Oncol Res; 2020 Jan; 26(1):79-89. PubMed ID: 30225784
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
[TBL] [Abstract][Full Text] [Related]
15. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
16. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
18. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
[TBL] [Abstract][Full Text] [Related]
19. Adequacy of cytology and small biopsy samples obtained with rapid onsite evaluation (ROSE) for predictive biomarker testing in non-small cell lung cancer.
Hendry S; Mamotte L; Mesbah Ardakani N; Leslie C; Tesfai Y; Grieu-Iacopetta F; Izaac K; Singh S; Ardakani R; Thomas M; Giardina T; Robinson C; Frost F; Amanuel B
Pathology; 2023 Dec; 55(7):917-921. PubMed ID: 37805343
[TBL] [Abstract][Full Text] [Related]
20. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy.
Song Z; Su H; Zhang Y
Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
